First, we set out to identify the releasate on full platelet activation. The releasate was evaluated in each individual by the determination of the dimethyl intensity ratio between the light (resting) and intermediate (activated) labeled peptides ( Figure 1A ). As expected, the vast majority of Objective-Platelet activation and subsequent protein release play an important role in healthy hemostasis and inflammatory responses, yet the identity and quantity of proteins in the platelet releasate are still debated. Here, we present a reversed releasate proteomics approach to determine unambiguously and quantitatively proteins released from activated platelets. Approach and Results-Isolated platelets were mock and fully stimulated after which the released proteins in the supernatant were removed. Using high-end proteomics technology (2D chromatography, stable isotope labeling, electron transfer dissociation, and high collision dissociation fragmentation) allowed us to quantitatively discriminate the released proteins from uncontrolled lysis products. Monitoring the copy numbers of ≈4500 platelet proteins, we observed that after stimulation via thrombin and collagen, only 124 (<3%) proteins were significantly released (P<0.05). The released proteins span a concentration range of ≥5 orders, as confirmed by ELISA. The released proteins were highly enriched in secretion tags and contained all known factors at high concentrations (>100 ng/mL, eg, thrombospondin, von Willebrand factor, and platelet factor 4). Interestingly, in the lower concentration range of the releasate many novel factors were identified. Conclusions-Our reversed releasate dataset forms the first unambiguous, in depth repository for molecular factors released by platelets. (Arterioscler Thromb Vasc Biol. 2013;33:1635-1638 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/In this large-scale proteomics study, we have developed a novel method to identify and quantify the platelet releasate using a reversed protein profiling approach. In contrast to previous approaches, this method is able to distinguish between releasate proteins and false positives with high accuracy. This approach yielded the first semiquantitative map of the platelet releasate which turned out to be surprisingly small.
I t is widely accepted that activated platelets release proteins into the circulation via various mechanisms, of which the α-granule route and shedding are the most established. The protein constituents of this releasate are associated with inflammation, coagulation, (tumor) angiogenesis, cell growth, and adhesion. [1] [2] [3] [4] [5] Although some of these factors are routinely assayed in the clinic, a comprehensive and unambiguous quantitative map of the platelet releasate is still at large. Previous releasate proteomics approaches relied on the isolation of α-granules from isolated platelets 6, 7 or the investigation of the isolated supernatant after in vitro platelet stimulation. 8, 9 However, these direct methods experience a high false-positive rate because of contamination by uncontrolled platelet lysis. Here, we take a reverse approach, monitoring quantitatively the concentration changes of all proteins in the platelets after platelet stimulation, whereby we assume that the released protein content should be detectable in the reduction of its level from the whole platelet proteome. For accuracy, our strategy uses stable isotope-labeling ( Figure 1A ) to discriminate the released proteins from uncontrolled lysis products. In other words, most platelet proteins do not change except the ones that are significantly released on activation.
Materials and Methods
Materials and Methods are available in the online-only Supplement. [10] [11] [12] [13] 
Results
Performing the reversed releasate quantitative proteomics experiments on 3 individuals resulted in the identification of 4375 unique proteins, of which 2970 (68%) could be quantified in ≥2 of 3 individuals ( Table I in the online-only Data Supplement). July 2013 proteins (>95%) had a resting/activated ratio close to 1.0. These ratios were highly reproducible between replicates with a median RSD between ratios of 9.6% (Table I and Figure I in the online-only Data Supplement). Using the statistical criteria described in the Methods section in the online-only Data Supplement, 124 proteins were observed to be significantly reduced in the activated platelets, in between 25% and 90% ( Figure 1B ; Table II in the onlineonly Data Supplement).
Measurement of the Releasate
Our approach allows us to quantify the full proteome of activated and mock-activated platelets and consequently the releasate. We semiquantitatively quantified 14-18 the entire detected proteome using a robust nonlinear fit of the molecular weight corrected spectral counts to a set of proteins with a known copy number per cell. 18 As we determined the fraction released for each protein in the previous section, we can use the average number of 2×10 8 platelets per milliliter blood to provide the concentration of each protein in the releasate in nanogram per milliliter blood (see Methods section in the online-only Data Supplement). We observed that the protein concentrations in the releasate span >5 orders of magnitude, ranging from highly abundant (µg/mL) hallmark releasate proteins, such as thrombospondin-1, platelet basic protein, and platelet factor 4, to lower abundant (pg/mL) novel releasate proteins, such as Tenascin-X and Kallistatin (Table  II in Table II in the online-only Data Supplement. CCL5 indicates chemokine (C-C motif) ligand 5 (also known as RANTES). Depicted are the gene names as deposited in the uniprot database at www.uniprot.org.
these numbers make sense, we performed ELISA experiments for several releasate proteins within the supernatant of the stimulated platelets (Figure 2A ). Finally, we classified the releasate according to major functional categories associated with platelet activation ( Figure 2B ).
Discussion
Overall, this comprehensive platelet proteome compares both qualitatively and quantitatively very well with the 4116 unique proteins identified by Burkhart et al 18 recently (Figures II and III in the online-only Data Supplement). The releasate as determined in our study is remarkably small in relation to previous reports, 8, 9 which by using a qualitative, instead of a quantitative, method probably contains many proteins originating from undesired platelet lysis (Actins, Talins, etc). As a benchmark for our approach, all currently known, important releasate proteins are present in our dataset, such as platelet factor 4, chemokine ligand 5, von Willebrand factor etc ( Figure 1B ; Figure IV in the onlineonly Data Supplement). Convincingly, 80% of the proteins identified in our releasate are documented, or predicted, to be secreted as based on SignalP 19 and Uniprot ( Figure 2B ; Figure V in the online-only Data Supplement). Closer inspection revealed that proteins involved in cell and matrix interactions, which is associated with wound healing, were among the highly released proteins (≈2 µg/mL). There are also several novel releasate proteins found in this study, as determined by String network analysis ( Figure 2B ; Figure  IV in the online-only Data Supplement). For example, Follistatin-like protein 1 has been found in osteoblasts and fibroblasts and characterized to play a role in the inflammatory pathway 20 ; filamin C plays a role in the crosslinking of actin in muscle cells 21 ; and tenascin-X binds to several collagen subtypes and plays a role in wound healing, as shown in patients with Ehlers-Danlos syndrome. 22 The calculated released concentrations match with the concentration determined by ELISA within a margin of 1 order, establishing that our calculated proteomics-based protein abundance is a good proxy for the actual content that is released.
In conclusion, we have developed a robust reversed releasate quantitative protein profiling method to more reliably identify and semiquantify the platelet releasate with high accuracy.
It covers an unprecedented depth of 5 orders of magnitude, exposing many novel molecular determinants of the platelet releasate to inspire further investigations into their roles. A1BG  APCS  APLP2  APP  AZGP1  CA1  CDC37L1  CLU  CPB2  CTSW  CYB5R1  DKK1  DNAJB11  DYRK1A  FAM3C  FSTL1  GALNT2  GAMT  GLG1  HIST1H1C  HIST1H4A  HIST2H2AB  LOXL3  LYZ  MAN1A1  MAN2A1  MMP1 CFB  CFH  CXCL3  IGHA1  IGHG1  IGHG2  IGHG3  IGHM  IGKC  IGLC2  ISLR  KV104  KV303  PF4 *, A documented or predicted secreted protein; °, a putative shedded protein because of the presence of ≥1 transmembrane domain predicted by hidden Markov model. 23 The colored boxes indicate the estimated amount of release. Depicted are the gene names as deposited in the uniprot database at www.uniprot.org.
